Nasdaq:US$15.84 (+0.63) | HKEX:HK$24.70 (-0.40) | AIM:£2.35 (+0.04)
Search Result
Previous Article   |   Next Article
Scientific Publications | 12 Dec 2021

ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.